Conference Coverage

High-intensity interval training has sustainable effects in patients with inflammatory arthritis


 

AT EULAR 2023

Long-lasting effects

Christopher Edwards, MBBS, MD, honorary consultant rheumatologist at University Hospital Southampton (England) NHS Foundation Trust Medicine, University of Southampton, was concerned about future maintenance of increased CRF. “I really wish we had data on these patients at 12 months as well, so we could see if the effects last even longer. Regarding intensity, there are clear indications that engaging in moderate and high-intensity workouts is more beneficial,” Dr. Norden said. “So, I would certainly recommend at least one high-intensity exercise session per week for those patients, while also incorporating lower and moderate-intensity exercises if desired. However, for individuals aiming to maximize their oxygen uptake, high-intensity exercise is considered the most effective approach.”

There is compelling evidence supporting the benefits of physical activity in improving disease activity among patients with IJD, making it a critical component of nonpharmacologic treatment. However, individuals with rheumatic and musculoskeletal conditions generally exhibit lower levels of physical activity, compared with their healthy counterparts. Recognizing the importance of CVD prevention in patients with IJD, EULAR recommends routine CVD screening for individuals diagnosed with IJD.

Ms. Norden and coauthors report no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

FDA puts partial hold on investigational alopecia areata drug deuruxolitinib
MDedge Internal Medicine
Normal CRP during RA flares: An ‘underappreciated, persistent phenotype’
MDedge Internal Medicine
Rheumatoid arthritis linked to increased Parkinson’s risk
MDedge Internal Medicine
Investigational drug peresolimab shows efficacy in patients with RA
MDedge Internal Medicine
FDA approves autoinjector pen for Humira biosimilar, Cyltezo
MDedge Internal Medicine
FDA approves Yuflyma as ninth adalimumab biosimilar
MDedge Internal Medicine
ILD risk elevated in RA, PsA after starting biologic or targeted synthetic DMARDs
MDedge Internal Medicine
Studies reveal nuances in efficacy, MACE risk between JAKi and TNFi
MDedge Internal Medicine
Is ChatGPT a friend or foe of medical publishing?
MDedge Internal Medicine
Why not both? Dual biologics for treatment-resistant RA and PsA
MDedge Internal Medicine